Login
$NERV
$2.21 -$0.09 (3.91%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Remy Luthringer Also a director
Chief Executive Officer and Executive Chairman of the Board of Directors
65 Not stated Not stated $9,354,184
Frederick Ahlholm
Chief Financial Officer
60 Not stated 2014 $2,469,211
Joseph H. Reilly
Chief Operating Officer
Title from the Form 3 dated Aug 10, 2026
Not stated Not stated Not stated Not reported
James O’Connor
Chief Business Officer and General Counsel
52 Since 2026
this year
Not stated Not reported
Anthony Aliquo
Chief Accounting Officer
Title from the Form 8-K dated Aug 10, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
4 of 6
stated in the proxy
Average tenure
9.3 years
from year joined
CEO also chairs the board
Yes
Dr. Remy Luthringer
Director Age On board Independent Other public boards 2025 pay Source
Dr. Remy Luthringer
65 2014
12 years
Not independent None stated Paid as CEO
Dr. David Kupfer
85 2015
11 years
Independent None stated $259,500
Jan van Heek
76 2014
12 years
Independent None stated $233,000
Hans Peter Hasler
70 2017
9 years
Independent HBM Healthcare Investments AG $235,000
Dr. Fouzia Laghrissi-Thode
63 2015
11 years
Independent None stated $227,250
Dr. Inderjit Kaul
69 2025
1 year
Not independent None stated $1,354,040

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

8 disclosed in the proxy filed Apr 23, 2026
Geoffrey Race
President of the Company and a Director of Mind-NRG, resigned effective March 31, 2026
£30,000
2026

Settlement Agreement under which the company agreed to payments and separation benefits in connection with Mr. Race's resignation, including a one-time severance payment.

With Mind-NRG SARL Open in proxy
Geoffrey Race
President of the Company and a Director of Mind-NRG, resigned effective March 31, 2026
£333 per hour
April 15, 2026 to April 14, 2027

Consultancy Agreement under which Mr. Race will provide consulting services to the company at an hourly fee.

Dr. Kaul
one of our directors
$450 per hour
six-month initial term

Consulting Agreement under which Dr. Kaul provides clinical trial and related services at an hourly rate.

Dr. Kaul
Director
Amount not stated

Option grant to Dr. Kaul, a consultant option for 0.7% of the Share Total with staged vesting, plus top-up options.

Federated Hermes Kaufmann Funds, the Farallon Funds, the Logos Funds, the Janus Funds, Atlas Private Holdings (Cayman) Ltd., the Vivo Funds, Seven Fleet Partners LP, Adage Capital Partners LP, Trails Edge Biotechnology Master Fund, LP, and Foresite Capital Fund VI LP
each a beneficial owner of, in the aggregate, more than 5% of our capital stock
Amount not stated

Participation in the 2025 Private Placement of Series A Preferred Stock and warrants.

Federated Hermes Kaufmann Funds and Boehringer Ingelheim International GmbH
stockholders entering into support agreements with the company
Amount not stated

Support Agreements under which these stockholders agreed to vote their shares for specified proposals in connection with the 2025 Private Placement.

Federated Hermes Kaufmann Funds and Boehringer Ingelheim International GmbH
Federated Hermes Kaufmann Funds were beneficial owners of more than 5%; Boehringer Ingelheim International GmbH became a beneficial owner of more than 5% through the 2023 Private Placement
Approximately $19.6 million
2023

Purchase of 1,425,000 shares of Common Stock and pre-funded warrants for 575,575 shares in the 2023 Private Placement.

Boehringer Ingelheim International GmbH
became a beneficial owner of more than 5% of our capital stock through the 2023 Private Placement
Amount not stated
2023

Right to designate a board observer until a Change of Control or until its holdings fall below 10% of Common Stock; observer designated August 29, 2023.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support